Dr. Mark F. Kozloff
Claim this profileIngalls Memorial Hospital
About Mark F. Kozloff
Education:
- Obtained a Medical degree (MD) from Rush Medical College, Chicago, IL.
- Completed Residency in Internal Medicine at the University of Chicago Hospitals.
- Undertook a Fellowship in Infectious Diseases at the University of Chicago Hospitals.
Experience:
- Currently serves as the Chief of Infectious Diseases at Ingalls Memorial Hospital.
- Holds the position of Associate Professor of Medicine at the University of Chicago Pritzker School of Medicine.
Area of expertise
Breast Cancer
Mark F. Kozloff has run 6 trials for Breast cancer. Some of their research focus areas include:
Colorectal Cancer
Mark F. Kozloff has run 5 trials for Colorectal Cancer. Some of their research focus areas include:
Affiliated Hospitals
Ingalls Memorial Hospital
Clinical Trials Mark F. Kozloff is currently running
Chemotherapy + Immunotherapy
for Esophageal and Gastric Cancer
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting
2 awards
Phase 3
2 criteria
Atezolizumab + Chemotherapy
for Neuroendocrine Carcinoma
This trial is testing a new treatment combining an immune-boosting drug with standard chemotherapy for patients with a specific type of aggressive cancer that has spread. The goal is to help the immune system fight the cancer and use chemotherapy to kill cancer cells.
Recruiting
1 award
Phase 2 & 3
10 criteria
More about Mark F. Kozloff
Clinical Trial Related
7 years of experience running clinical trials · Led 26 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Mark F. Kozloff has experience with
- Atezolizumab
- Fluorouracil
- Carboplatin
- Nivolumab
- Irinotecan
- Leucovorin Calcium
Breakdown of trials Mark F. Kozloff has run
Breast cancer
Colorectal Cancer
Breast Cancer
Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Mark F. Kozloff specialize in?
Mark F. Kozloff focuses on Breast cancer and Colorectal Cancer. In particular, much of their work with Breast cancer has involved Stage IV patients, or patients who are Stage III.
Is Mark F. Kozloff currently recruiting for clinical trials?
Yes, Mark F. Kozloff is currently recruiting for 4 clinical trials in Harvey Illinois. If you're interested in participating, you should apply.
Are there any treatments that Mark F. Kozloff has studied deeply?
Yes, Mark F. Kozloff has studied treatments such as Atezolizumab, Fluorouracil, Carboplatin.
What is the best way to schedule an appointment with Mark F. Kozloff?
Apply for one of the trials that Mark F. Kozloff is conducting.
What is the office address of Mark F. Kozloff?
The office of Mark F. Kozloff is located at: Ingalls Memorial Hospital, Harvey, Illinois 60426 United States. This is the address for their practice at the Ingalls Memorial Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.